Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENELUX CorpGNLX · Entity 1116 | Chief Scientific Officer | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENELUX Corp
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 258,688 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Sale · Disposed 9,683 · Balance 258,688 F1: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2: The weighted average sale price for the transaction reported was $2.7531, and the range of prices were between $2.70 and $2.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.
F2: The weighted average sale price for the transaction reported was $2.7531, and the range of prices were between $2.70 and $2.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 23:05 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 9,683 | $2.75 | $26,658.27 |
DisclosureSEC source: 0001493152-26-041283 · ownership.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,688 F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $2.7531, and the range of prices were between $2.70 and $2.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided Read SEC document |
| August 04, 2026 Filed Aug 5, 2026 00:20 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 653 | $2.94 | $1,922.04 |
DisclosureSEC source: 0001493152-26-036077 · ownership.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,371 F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $2.9434, and the range of prices were between $2.93 and $2.975. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 23:05 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 119,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-029414 · ownership.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,024 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter. Read SEC document |
| May 11, 2026 Filed May 13, 2026 00:30 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 605 | $2.97 | $1,798.42 |
DisclosureSEC source: 0001493152-26-022567 · ownership.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,706 F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $2.9726, and the range of prices were between $2.95 and $3.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 21:00 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 906 | $2.42 | $2,192.52 |
DisclosureSEC source: 0001493152-26-012970 · ownership.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,938 F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. Read SEC document |
| November 17, 2025 Filed Dec 12, 2025 01:50 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 973 | $5.37 | $5,224.43 |
DisclosureSEC source: 0001493152-25-027338 · ownership.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,844 F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2 · balance_after: The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:15 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $3.33 | Not disclosed |
DisclosureSEC source: 0001641172-25-026397 · ownership.xml · derivative · entry 4 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common stock · 65,000 shares Expires 2033-09-10 F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:15 UTC | GENELUX Corp GNLX · Entity 1116 | Disposition to issuerStock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $22.40 | Not disclosed |
DisclosureSEC source: 0001641172-25-026397 · ownership.xml · derivative · entry 3 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 65,000 shares Expires 2033-09-10 F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:15 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (Right to Buy) · Derivative | 207,652 | Not disclosed Strike: $3.33 | Not disclosed |
DisclosureSEC source: 0001641172-25-026397 · ownership.xml · derivative · entry 2 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,652 Underlying: Common stock · 207,652 shares Expires 2029-09-20 F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. F1 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:15 UTC | GENELUX Corp GNLX · Entity 1116 | Disposition to issuerStock Option (Right to Buy) · Derivative | 207,652 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0001641172-25-026397 · ownership.xml · derivative · entry 1 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 207,652 shares Expires 2029-09-20 F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. F1 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (Right to Buy) · Derivative | 134,520 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001641172-25-026001 · ownership.xml · derivative · entry 2 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,520 Underlying: Common stock · 134,520 shares Expires 2035-08-26 F3 · derivative.exercise_date: The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 101,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-026001 · ownership.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,036 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter. F2 · balance_after: Includes 916 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| August 21, 2025 Filed Dec 12, 2025 01:50 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 3,219 | $3.36 | $10,807.47 |
DisclosureSEC source: 0001493152-25-027338 · ownership.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · SVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,817 F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2 · balance_after: The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025. Read SEC document |
| May 12, 2025 Filed May 13, 2025 21:05 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 5,579 | $2.92 | $16,290.68 |
DisclosureSEC source: 0001415889-25-012807 · form4-05132025_050533.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,640 F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. Read SEC document |
| March 14, 2025 Filed Apr 17, 2025 20:56 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 13,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010879 · form4-04172025_080423.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,219 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025. Read SEC document |
| December 18, 2024 Filed Dec 21, 2024 01:46 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001415889-24-030005 · form4-12212024_011230.xml · derivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2034-12-17 F2 · derivative.exercise_date: 25% of the shares vest on August 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| December 18, 2024 Filed Dec 21, 2024 01:46 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 29,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030005 · form4-12212024_011230.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,869 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. 25% of the RSUs vest on August 1, 2025, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. Read SEC document |
| June 24, 2024 Filed Jul 8, 2024 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 6,849 | $2.12 | $14,519.88 |
DisclosureSEC source: 0001415889-24-019343 · form4-07082024_040709.xml · nonDerivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,869 F3 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of RSUs. Read SEC document |
| May 29, 2024 Filed Jun 8, 2024 01:40 UTC | GENELUX Corp GNLX · Entity 1116 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 2,500 | Not disclosed Strike: $5.25 | Not disclosed |
DisclosureSEC source: 0001415889-24-016101 · form4-06072024_090610.xml · derivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2029-05-29 F1 · kind: The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 15, 2023. The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs. F2 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00. Read SEC document |
| May 29, 2024 Filed Jun 8, 2024 01:40 UTC | GENELUX Corp GNLX · Entity 1116 | PurchaseCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-016101 · form4-06072024_090610.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The Reporting Person's purchase reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of common stock on December 15, 2023. The Reporting Person has agreed to pay to the Issuer the profit realized in connection with the short-swing transaction, less transaction costs. F2 · price: The reported securities consist of shares of common stock sold together with accompanying warrants to purchase common stock. The combined price of each share of common stock offered together with one warrant was $4.00. Read SEC document |
| March 14, 2024 Filed Jul 8, 2024 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 11,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019343 · form4-07082024_040709.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,718 F2 · kind: Represents RSUs that are fully vested as of March 14, 2024. Read SEC document |
| February 19, 2024 Filed Jul 8, 2024 20:30 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 3,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019343 · form4-07082024_040709.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,161 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 21:15 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 5,803 | $14.18 | $82,265.07 |
DisclosureSEC source: 0001209191-23-058954 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The weighted average sale price for the transaction reported was $14.1763, and the range of prices were between $13.80 and $14.535. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 21:15 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 26,732 | $12.94 | $345,914.75 |
DisclosureSEC source: 0001209191-23-058954 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,803 F1 · price: The weighted average sale price for the transaction reported was $12.9401, and the range of prices were between $12.69 and $13.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:57 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 36,800 | $11.85 | $435,995.36 |
DisclosureSEC source: 0001209191-23-057975 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,535 F1 · price: The weighted average sale price for the transaction reported was $11.8477, and the range of prices were between $11.51 and $12.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 21:15 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 18,665 | $10.26 | $191,555.16 |
DisclosureSEC source: 0001209191-23-056455 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,335 F1 · price: The weighted average sale price for the transaction reported was $10.2628, and the range of prices were between $9.91 and $10.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 21:15 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 14,594 | $11.26 | $164,261.31 |
DisclosureSEC source: 0001209191-23-056237 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,000 F2 · price: The weighted average sale price for the transaction reported was $11.2554, and the range of prices were between $11.00 and $11.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 21:15 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 3,541 | $13.04 | $46,169.68 |
DisclosureSEC source: 0001209191-23-056237 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,594 F1 · price: The weighted average sale price for the transaction reported was $13.0386, and the range of prices were between $13.00 and $13.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 24, 2023 Filed Oct 25, 2023 20:15 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-053554 · doc4.xml · derivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,653 Underlying: Common Stock · 5,200 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 24, 2023 Filed Oct 25, 2023 20:15 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 5,200 | $19.11 | $99,351.20 |
DisclosureSEC source: 0001209191-23-053554 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $19.106, and the range of prices were between $19.00 and $19.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 24, 2023 Filed Oct 25, 2023 20:15 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionCommon Stock | 5,200 | $6.00 | $31,200.00 |
DisclosureSEC source: 0001209191-23-053554 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052621 · doc4.xml · derivative · entry 4 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,853 Underlying: Common Stock · 5,200 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 400 | $22.91 | $9,162.40 |
DisclosureSEC source: 0001209191-23-052621 · doc4.xml · nonDerivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $22.906, and the range of prices were between $22.82 and $22.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 4,800 | $21.94 | $105,299.52 |
DisclosureSEC source: 0001209191-23-052621 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,535 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $21.9374, and the range of prices were between $21.54 and $22.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionCommon Stock | 5,200 | $6.00 | $31,200.00 |
DisclosureSEC source: 0001209191-23-052621 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · derivative · entry 5 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,053 Underlying: Common Stock · 5,200 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 2,203 | $24.46 | $53,890.45 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · nonDerivative · entry 4 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F4 · price: The weighted average sale price for the transaction reported was $24.4623, and the range of prices were between $24.24 and $24.755. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 1,114 | $23.51 | $26,195.15 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · nonDerivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,338 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $23.5145, and the range of prices were between $23.16 and $24.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 1,883 | $22.54 | $42,442.26 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,452 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $22.5397, and the range of prices were between $22.13 and $23.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 26, 2023 Filed Sep 27, 2023 20:10 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionCommon Stock | 5,200 | $6.00 | $31,200.00 |
DisclosureSEC source: 0001209191-23-050643 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:35 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050282 · doc4.xml · derivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,253 Underlying: Common Stock · 6,000 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:35 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 6,000 | $27.96 | $167,785.80 |
DisclosureSEC source: 0001209191-23-050282 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $27.9643, and the range of prices were between $27.95 and $28.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 20:35 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionCommon Stock | 6,000 | $6.00 | $36,000.00 |
DisclosureSEC source: 0001209191-23-050282 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:13 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionStock Option (right to buy) · Derivative | 10,400 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049841 · doc4.xml · derivative · entry 4 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,253 Underlying: Common Stock · 10,400 shares Expires 2029-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:13 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 4,675 | $22.29 | $104,211.83 |
DisclosureSEC source: 0001209191-23-049841 · doc4.xml · nonDerivative · entry 3 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $22.2913, and the range of prices were between $22.02 and $22.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:13 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 5,725 | $21.56 | $123,418.41 |
DisclosureSEC source: 0001209191-23-049841 · doc4.xml · nonDerivative · entry 2 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,810 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $21.5578, and the range of prices were between $21.01 and $21.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 00:13 UTC | GENELUX Corp GNLX · Entity 1116 | Exercise / conversionCommon Stock | 10,400 | $6.00 | $62,400.00 |
DisclosureSEC source: 0001209191-23-049841 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2023 Filed Sep 16, 2023 00:06 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 29,800 | $21.14 | $629,927.30 |
DisclosureSEC source: 0001209191-23-049673 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,135 F1 · price: The weighted average sale price for the transaction reported was $21.1385, and the range of prices were between $21.00 and $21.58. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 20:24 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001209191-23-049101 · doc4.xml · derivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-09-10 F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| August 30, 2023 Filed Aug 30, 2023 23:22 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 19,800 | $24.70 | $489,060.00 |
DisclosureSEC source: 0001209191-23-047784 · doc4.xml · nonDerivative · entry 1 Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,935 F1 · price: The weighted average sale price for the transaction reported was $24.70, and the range of prices were between $24.70 and $24.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.